Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix's micorarray patents, the firms announced this week.

Invitrogen is being tight-lipped about which patents it has licensed from Affymetrix and whether it intends to expand into the field of DNA microarrays, but it is clear the firm intends to expand its franchise in the non-coding RNA tools market.

"This was an opportunity for us to bring in some capabilities through additional intellectual property," said Greg Geissman, an Invitrogen spokesman.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.